Home › Neurologic Diseases › Virginia › Arlington
Neurologic Diseases clinical trials in Arlington, VA
4 studies for Neurologic Diseases are looking for participants at sites in and around Arlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
RecruitingPhase 2
- Vima Site #066, Arlington
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
RecruitingPhase 2
- Re:Cognition Health, Fairfax · 11 mi away
Product Surveillance Registry
RecruitingObservational study
- Falls Church, Falls Church · 4 mi away
- Fairfax, Fairfax · 11 mi away
Open-label Extension Study in Participants With Early Alzheimer's Disease
RecruitingPhase 2
- GSK Investigational Site, Fairfax · 11 mi away
About Neurologic Diseases
Your nervous system includes your brain, spinal cord, and nerves. Learn about neurologic diseases, including their symptoms, causes, and treatments.
More about Neurologic Diseases on MedlinePlus
Neurologic Diseases trials in other cities
- Boston, MA10 studies
- Orlando, FL7 studies
- Miami, FL7 studies
- Washington, DC7 studies
- Philadelphia, PA7 studies
- Dallas, TX7 studies
- Houston, TX7 studies
- San Diego, CA6 studies
- St. Louis, MO6 studies
- Austin, TX5 studies
- New York City, NY5 studies
- Los Angeles, CA5 studies
Other studies in Arlington
- Non-Small Cell Lung Cancer111 studies
- Colorectal Cancer54 studies
- Metastatic Cancer52 studies
- Cancer (all types)52 studies
- Breast Cancer50 studies
- Ovarian Cancer47 studies
- Lung Cancer42 studies
- Endometrial Cancer41 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Small Cell Lung Cancer22 studies
- Triple-Negative Breast Cancer21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.